| Pipeline
Zenagamtide, formerly called amycretin, is an investigational drug from Novo Nordisk that acts on the GLP-1 and amylin receptors. AMAZE 9 is the phase 3 trial of its once-daily tablet. It plans about 950 adults with overweight or obesity. People with diabetes are excluded, and so are people previously treated with a GLP-1-based or amylin drug. ClinicalTrials.gov lists a start date of August 31, 2026. The main measure is percent change in body weight at week 76, and completion is listed for August 2028.
Novo's third-quarter investor presentation shows the tested once-daily doses as 6 mg, 12 mg, 25 mg, 50 mg and 2 x 50 mg, each compared with placebo. Novo says it plans a biologics license application for the tablet supported by bridging data. Bridging data link the tablet trial to the injectable program, AMAZE, by modeling how much drug reaches the blood and what effect follows. Novo lists a possible launch in 2029.
Worth knowing: These are plans and trial arms, not results. No AMAZE 9 data exist, and the doses are the trial's design, not a recommendation for anyone. Earlier weight-loss estimates for zenagamtide come from smaller studies of different lengths and different forms, so they do not show that the tablet and the injection work alike. Open questions are how much extra weight loss the higher doses add and how many people stop because of stomach side effects. Zenagamtide is not approved anywhere.
Related: Amycretin (zenagamtide) medicine page | Novo Nordisk tracker | Drug pipeline
Source: ClinicalTrials.gov, AMAZE 9 (NCT07720271) Trial registry. Novo Nordisk Q3 2026 investor presentation, slides 57 and 58, on the Novo Nordisk investor site Company presentation.